uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases in the United States. The company offers HEMGENIX that allows people living with hemophilia B to produce factor IX, which can lower the risk of bleeding. Its lead product candidate is AMT-130, a gene therapy candidate, which is in Phase I/II clinical study for the treatment of Huntington's disease. The company also develops AMT-260, which is in Phase I/IIa clinical trial for the treatment of mesial temporal lobe epilepsy; AMT-162, which is in Phase I/IIa clinical trial to treat superoxide dismutase enzyme-amyotrophic lateral sclerosis; and AMT-191, an investigational gene therapy candidate which is in phase I/IIa clinical trial for the treatment of fabry disease. It has a licensing agreement with Apic Bio to develop, manufacture, and commercialize intrathecally administered investigational gene therapy for ALS caused by mutations in SOD-1; and development and commercial supply agreement with CLS Bhering. uniQure N.V. was founded in 1998 and is headquartered in Amsterdam, the Netherlands.

uniQure N.V.

Stifel Nicolaus analyst Paul Matteis maintained a Buy rating on uniQure today and set a price target of $71.00. According to TipRanks, Matteis is a...

Stifel Nicolaus Sticks to Its Buy Rating for uniQure (QURE)

Analysts are intrested in these 5 stocks: ( ($PSA) ), ( ($HUM) ), ( ($QURE) ), ( ($SKHY) ) and ( ($FVRR) ). Here is a breakdown of their recent


Humana, Public Storage, uniQure, SK Hynix, Fiverr Trending

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on uniQure (QURE) and Tenax Therapeutics (TENX) with bu...

Analysts Offer Insights on Healthcare Companies: uniQure (QURE) and Tenax Therapeutics (TENX)

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Teladoc (TDOC), Fortrea Holdings Inc. (FTRE) and u...

Analysts Offer Insights on Healthcare Companies: Teladoc (TDOC), Fortrea Holdings Inc. (FTRE) and uniQure (QURE)

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on AbCellera Biologics (ABCL) and uniQure (QURE) with b...

	A	B	C	D
1	Symbol	Price	Change	Volume
2	QURE	$48.62	+3.31%	956.50K
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	QURE	$48.62	+3.3%	956.50K
3
4
5
6

QURE

Get uniQure N.V. Data in Excel

Get uniQure N.V. Data in Excel